Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Short Interest Update

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) was the target of a significant growth in short interest in April. As of April 15th, there was short interest totalling 15,300 shares, a growth of 31.9% from the March 31st total of 11,600 shares. Based on an average daily volume of 596,100 shares, the short-interest ratio is currently 0.0 days.

Analyst Ratings Changes

Separately, Maxim Group reduced their price objective on Quoin Pharmaceuticals from $15.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, March 15th.

Quoin Pharmaceuticals Price Performance

Quoin Pharmaceuticals stock traded up $0.02 during mid-day trading on Tuesday, hitting $0.71. The company’s stock had a trading volume of 33,213 shares, compared to its average volume of 475,540. The business has a 50 day moving average price of $1.21 and a 200-day moving average price of $3.14. Quoin Pharmaceuticals has a 12 month low of $0.60 and a 12 month high of $12.00. The stock has a market cap of $2.61 million, a price-to-earnings ratio of -0.07 and a beta of 1.81.

Quoin Pharmaceuticals (NASDAQ:QNRX) last posted its earnings results on Wednesday, March 13th. The company reported ($2.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.37) by $0.29. On average, equities research analysts expect that Quoin Pharmaceuticals will post -9.36 earnings per share for the current fiscal year.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.